The Block Organ Transplant Purchases from China Act of 2025 amends Medicare and Medicaid payment law, the Public Health Service Act, and the National Organ Transplant Act to prohibit certain organ transplants tied to the People’s Republic of China or to organs not procured through the Organ Procurement and Transplantation Network (OPTN). Beginning January 1, 2026, federal programs and most private group and individual health plans may not cover these transplants or related items and services, except narrowly for life‑saving care after the fact.
The bill also makes it a federal offense for a health care provider to knowingly furnish a prohibited transplant, authorizes state and federal civil enforcement with penalties equal to three times the cost of the transplant as set by HHS, and directs HHS to issue rules to identify prohibited items/services and to determine cost for penalty calculations. For compliance officers, transplant program directors, and payers, the law would add provenance documentation, claims-screening, and significant enforcement risk to cross‑border transplant activity and post‑transplant billing.
At a Glance
What It Does
The bill adds a new Medicare/Medicaid payment exclusion and a new PHS Act coverage bar for 'prohibited organ transplants'—defined as transplants that occur in the PRC or that use organs not procured via the OPTN. It also amends the National Organ Transplant Act to ban providers from furnishing such transplants and imposes criminal and civil penalties for knowing violations.
Who It Affects
Transplant centers and clinicians, federal and state payers, private group and individual health insurers, organ procurement organizations and the OPTN, and patients who travel abroad for transplantation. HHS, state attorneys general, and the Department of Justice gain enforcement responsibilities.
Why It Matters
This is an extraterritorial-targeted compliance regime: it ties payment and criminal liability to the geographic origin and provenance of donated organs. The combination of coverage denial, triple-damages civil penalties, and criminal exposure creates new compliance and documentation obligations that will change how transplants tied to international providers are handled.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill establishes a new, tripartite approach: (1) it instructs Medicare and Medicaid not to pay for certain transplants or related services after a set date; (2) it prohibits private group and individual health plans from covering the same; and (3) it criminalizes and civilly penalizes providers who knowingly perform these transplants. The operative trigger is a 'prohibited organ transplant,' a term defined in the National Organ Transplant Act amendment as any transplant of a long list of organs that either occurs in the People’s Republic of China or involves an organ not procured through the OPTN.
Practically, the coverage prohibitions extend beyond the operating room. The bill bars payment for follow‑up appointments, labs, and drugs provided in connection with a prohibited transplant unless the care is strictly to save the patient’s life after the transplant.
That creates two distinct billing paths for payers and providers: routine post‑op and chronic care tied to the transplant can be denied, while emergency or life‑saving interventions must still be furnished and can be paid for. The PHS Act change makes the ban applicable to group health plans and health insurance issuers, so most employer and individual market coverage will be affected.Enforcement is both criminal and civil.
The statute creates a misdemeanor-level federal crime (up to two years’ imprisonment and fines) for providers who 'knowingly' furnish a prohibited transplant. Separately, state attorneys general or the U.S. Attorney General can pursue civil actions that impose a penalty equal to three times the cost of the transplant or related items, with the HHS Secretary designated to set the method for computing those costs.
HHS must issue rules to identify which items and services are prohibited and to set the cost metric used in civil penalties, and the bill ties those rulemaking requirements to the January 1, 2026 effective date.For compliance teams, the immediate practical tasks the bill creates are documentation and claims-control: verifying where a transplant occurred, whether the organ was procured through OPTN, flagging claims for denial or emergency exception, and preparing for potential subpoenas or enforcement actions. For clinical programs, the statute forces a distinction between care that is forbidden to be billed and care that must still be provided for life preservation, requiring internal clinical‑billing protocols and informed‑consent conversations with patients considering travel for transplantation.
The Five Things You Need to Know
The bill defines a 'prohibited organ transplant' as a transplant of a specified human organ that either occurs in the People’s Republic of China or uses an organ not procured through the OPTN.
Medicare, Medicaid, and most private group and individual health plans may not pay for prohibited transplants or associated items/services furnished on or after January 1, 2026, except payments may be made for care provided to save the life of the recipient after the transplant.
The NOTA amendment makes it a federal crime for a health care provider who knowingly performs a prohibited transplant, punishable by up to 2 years’ imprisonment and fines.
State attorneys general or the U.S. Attorney General may seek civil penalties equal to three times the cost of the prohibited transplant or related services, with HHS responsible for specifying how those costs are calculated.
HHS must issue rules by January 1, 2026 to identify the prohibited items and services and to determine the cost metric used for civil penalties.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the measure as the 'Block Organ Transplant Purchases from China Act of 2025' or the 'Block Act of 2025.' This is a formal label that has no legal effect on the substantive mechanics but is how the statute will be cited in future references.
Adds a Medicare payment exclusion for prohibited transplants and related services
The bill inserts a new Medicare exclusion that prevents payment for a 'prohibited organ transplant' or for items and services furnished in connection with such a transplant on or after January 1, 2026, with an exception only for services necessary to save the life of an individual after receiving such a transplant. Administratively, CMS will need to add denial codes, update claims adjudication guidance, and set documentation standards to verify whether a claim involves a prohibited transplant.
State plan requirement to deny payment and extension to managed care
The bill conditions federal Medicaid participation on state plans providing that no Medicaid payment may be made for a prohibited transplant or associated services, except life‑saving aftercare. It also amends the statute on federal financial participation to make the exclusion applicable to expenditures for such transplants, and explicitly applies to managed care entities by adjusting cross‑references. States will need to incorporate the bar into their Medicaid plan documents and managed care contracts, and Medicaid agencies will have to instruct MCOs on claim denials and emergency exceptions.
Private insurers and group health plans barred from covering prohibited transplants
The bill adds a new section to the PHS Act prohibiting group health plans and health insurance issuers offering group or individual coverage from providing coverage for prohibited transplants or related items and services, again with the life‑saving exception. That language reaches most employer and individual market policies administered under federal law, forcing insurers to alter benefit designs, preauthorization rules, and provider directories to address international transplant claims.
Provider-level ban and criminal/civil enforcement
This is the operational enforcement core: starting January 1, 2026, no 'health care provider' may furnish a prohibited organ transplant or related items/services except to save a life after such a transplant. The section establishes a criminal penalty for knowing violations (up to two years) and authorizes civil suits by state attorneys general or the U.S. Attorney General that impose a penalty equal to three times the cost of the transplant as determined by HHS. The statute defines the list of covered tissues and organs broadly and includes OPTN provenance as a key legality test.
HHS rulemaking to define prohibited items/services and set cost metrics
HHS must issue rules to identify what items and services are prohibited under the new payment bars and how the 'cost of furnishing' a prohibited transplant will be determined for civil penalty calculations. Those regulations will be central to enforcement because they will define the scope of prohibited ancillary services (e.g., specific lab tests or pharmaceuticals) and the arithmetic for triple-damages civil penalties.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Organ procurement organizations and the OPTN — the bill reinforces the OPTN's centrality by tying lawful transplants to OPTN procurement, which may strengthen oversight and increase reliance on its matching and allocation systems.
- Patients harmed by organ trafficking or coerced donation — by creating a payment and legal disincentive for transplants tied to China or outside OPTN procurement, the statute aims to reduce demand for organs obtained through unethical or illicit means.
- U.S. transplant programs acting within established protocols — the law protects programs that follow OPTN procurement rules from competing with transplants sourced through opaque cross‑border channels.
Who Bears the Cost
- U.S. transplant centers and clinicians — they face criminal and civil exposure if they knowingly participate in prohibited transplants, and they must implement new intake, documentation, and billing controls to avoid penalties.
- Payers (Medicare, Medicaid, private insurers) — payers must update claims-processing systems, authorization and denial rules, and provider guidance, and may incur contested claim litigation and administrative overhead.
- Patients who travel abroad for transplants — individuals who seek transplants in the PRC or via non‑OPTN channels risk losing coverage for the transplant and for routine post‑transplant care, potentially shifting significant costs onto themselves or causing gaps in follow‑up care.
- State attorneys general and DOJ — enforcement duties may increase as the bill authorizes civil actions; states must allocate resources to investigate provenance and pursue treble‑damages claims.
Key Issues
The Core Tension
The central dilemma is between deterring unethical or trafficked organ transplants by cutting off payment and imposing penalties, and preserving patient safety and access to necessary follow‑up care: aggressive enforcement reduces demand for illicit organs but risks denying ordinary post‑operative care or deterring providers from treating complications unless the statute and implementing rules create precise, workable standards for provenance, exceptions, and proof.
The bill raises several implementation and operational problems that are not resolved in the statutory text. First, the compliance hinge is provenance: determining where a transplant occurred and whether an organ was procured through the OPTN.
That requires documentary standards, cross‑border verification, and thresholds for admissible evidence; without clear guidance, insurers and providers will struggle to apply the payment bars consistently. Second, the 'knowingly' mens rea for criminal and civil liability will import difficult factual inquiries into provider knowledge and intent—proving that a surgeon or hospital 'knew' an organ had illicit provenance may be challenging, while the risk of criminal exposure could incentivize overly cautious behavior, including refusal to treat complications.
The life‑saving exception mitigates patient‑safety risk on its face, but it is narrow and operationally vague. What qualifies as 'to save the life of an individual after such individual receives such a prohibited organ transplant' will require tight clinical and billing rules to avoid disparate application; absent that, hospitals may either overuse the exception, undermining the statute, or withhold necessary non‑emergency follow‑up for fear of payment denial or liability.
Finally, the civil penalty formula—three times the 'cost' as determined by HHS—creates uncertainty and potentially large financial exposure; the method HHS uses to compute 'cost of furnishing' will shape deterrence and litigation risk, but the statute gives little direction on competitive neutrality or adjustments for services rendered outside the United States.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.